all of any of 125-03 Response - decreased 125-03 Response - increased 30 min GTT hyperglycemic 30 min GTT hyperglycemic (male) 30 min GTT hyperoglycemic (female) 30 min GTT hypoglycemic 30 min GTT hypoglycemic (female) 30 min GTT hypoglycemic (male) adenovirus infection of macrophages - decreased adenovirus infection of macrophages - increased adipose tissue anemia Anophthalmia Aut: Interaction - decreased Aut: Interaction - increased autoimmunity behavior/neurological Blood Analysis EO% - decreased Blood Analysis EO% - increased Blood Analysis Hb - decreased Blood Analysis Hb - increased Blood Analysis HCT - decreased Blood Analysis HCT - increased Blood Analysis LY# - decreased Blood Analysis LY# - increased Blood Analysis MCH - decreased Blood Analysis MCH - increased Blood Analysis MCHC - decreased Blood Analysis MCHC - increased Blood Analysis MCV - decreased Blood Analysis MCV - increased Blood Analysis MO# - decreased Blood Analysis MO# - increased Blood Analysis NE# - decreased Blood Analysis NE# - increased Blood Analysis Platelet Count - decreased Blood Analysis Platelet Count - increased Blood Analysis RBC - decreased Blood Analysis RBC - increased Blood Analysis RDW - decreased Blood Analysis RDW - increased Blood Analysis WBC - decreased Blood Analysis WBC - increased Blood Pressure: Pooled HR - decreased Blood Pressure: Pooled HR - increased Blood Pressure: Pooled SBP - decreased Blood Pressure: Pooled SBP - increased Body Weight - decreased Body Weight - increased Body Weight (BP, z-score, female) - decreased Body Weight (BP, z-score, female) - increased Body Weight (BP, z-score, male) - decreased Body Weight (BP, z-score, male) - increased Body Weight (DSS Female) - decreased Body Weight (DSS Female) - increased Body Weight (DSS Male) - decreased Body Weight (DSS Male) - increased Body Weight (DSS) - decreased Body Weight (DSS) - increased Body Weight (DSS, Day10) - decreased Body Weight (DSS, Day10) - increased Body Weight (DSS, Day7) - decreased Body Weight (DSS, Day7) - increased Body Weight (DSS, z-score) - decreased Body Weight (DSS, z-score) - increased Body Weight (DSS, z-score, female) - decreased Body Weight (DSS, z-score, female) - increased Body Weight (DSS, z-score, male) - decreased Body Weight (DSS, z-score, male) - increased Body Weight (Female) - decreased Body Weight (Female) - increased Body Weight (Male) - decreased Body Weight (Male) - increased Body Weight (Z-score) - decreased Body Weight (Z-score) - increased Body Weight (Z-score, female) - decreased Body Weight (Z-score, female) - increased Body Weight (Z-score, male) - decreased Body Weight (Z-score, male) - increased Bone: Femur Length (AI, residual) - decreased Bone: Femur Length (AI, residual) - increased Bone: Femur Length (AI, residual, female) - decreased Bone: Femur Length (AI, residual, female) - increased Bone: Femur Length (AI, residual, male) - decreased Bone: Femur Length (AI, residual, male) - increased Bone: Fore Hip Distance (AI) - decreased Bone: Fore Hip Distance (AI) - increased Bone: Fore Hip Distance (AI, female) - decreased Bone: Fore Hip Distance (AI, female) - increased Bone: Fore Hip Distance (AI, male) - decreased Bone: Fore Hip Distance (AI, male) - increased Bone: Hind Hip Distance (AI) - decreased Bone: Hind Hip Distance (AI) - increased Bone: Hind Hip Distance (AI, female) - decreased Bone: Hind Hip Distance (AI, female) - increased Bone: Hind Hip Distance (AI, male) - decreased Bone: Hind Hip Distance (AI, male) - increased Bone: Hip Ratio (AI) - decreased Bone: Hip Ratio (AI) - increased Bone: Pelvis Length (AI, residual) - decreased Bone: Pelvis Length (AI, residual) - increased Bone: Pelvis Length (AI, residual, female) - decreased Bone: Pelvis Length (AI, residual, female) - increased Bone: Pelvis Length (AI, residual, male) - decreased Bone: Pelvis Length (AI, residual, male) - increased Bone: Spine Deformity (female) Bone: Spine Deformity (male) Bone: Tibia Length (AI, residual) - decreased Bone: Tibia Length (AI, residual) - increased Bone: Tibia Length (AI, residual, female) - decreased Bone: Tibia Length (AI, residual, female) - increased Bone: Tibia Length (AI, residual, male) - decreased Bone: Tibia Length (AI, residual, male) - increased cardiovascular system CD8 response - decreased cellular phenotype craniofacial CTL killing - decreased CTL killing - increased CTL killing dominant epitope - decreased CTL killing dominant epitope - increased CTL killing subdominant epitope - decreased CTL killing subdominant epitope - increased digestive/alimentary dsDNA Antibody - decreased dsDNA Antibody - increased dsDNA induced type I IFN production - decreased dsDNA induced type I IFN production - increased DSS: resistant DSS: resistant day 10 DSS: resistant day 7 DSS: sensitive day 10 DSS: sensitive day 7 embryogenesis endocrine/exocrine gland extracellular cGAMP: high response extracellular cGAMP: low response eye: micro-ophthalmia Eye: SL-OCT BM to ILM thickness - decreased Eye: SL-OCT BM to ILM thickness - increased Eye: SL-OCT BM to ILM thickness (base) - decreased Eye: SL-OCT BM to ILM thickness (base) - increased Eye: SL-OCT BM to ILM thickness (delta) - decreased Eye: SL-OCT BM to ILM thickness (delta) - increased Eye: SL-OCT INL to ILM thickness - decreased Eye: SL-OCT INL to ILM thickness - increased Eye: SL-OCT INL to ILM thickness (base) - decreased Eye: SL-OCT INL to ILM thickness (base) - increased Eye: SL-OCT INL to ILM thickness (delta) - decreased Eye: SL-OCT INL to ILM thickness (delta) - increased Eye: SL-OCT IPL to ILM thickness - decreased Eye: SL-OCT IPL to ILM thickness - increased Eye: SL-OCT IPL to ILM thickness (base) - decreased Eye: SL-OCT IPL to ILM thickness (base) - increased Eye: SL-OCT IPL to ILM thickness (delta) - decreased Eye: SL-OCT IPL to ILM thickness (delta) - increased FACS B cells - decreased FACS B cells - increased FACS B:T cells - decreased FACS B:T cells - increased FACS B1 cells - decreased FACS B1 cells - increased FACS B1a cells - decreased FACS B1a cells - increased FACS B1a cells in B1 cells - decreased FACS B1a cells in B1 cells - increased FACS B1b cells - decreased FACS B1b cells - increased FACS B1b cells in B1 cells - decreased FACS B1b cells in B1 cells - increased FACS B2 cells - decreased FACS B2 cells - increased FACS B220 MFI - decreased FACS B220 MFI - increased FACS CD11b+ DCs (gated in CD11c+ cells) - decreased FACS CD11b+ DCs (gated in CD11c+ cells) - increased FACS CD11c+ DCs - decreased FACS CD11c+ DCs - increased FACS CD4:CD8 - decreased FACS CD4:CD8 - increased FACS CD4+ T cells - decreased FACS CD4+ T cells - increased FACS CD4+ T cells in CD3+ T cells - decreased FACS CD4+ T cells in CD3+ T cells - increased FACS CD44+ CD4 MFI - decreased FACS CD44+ CD4 MFI - increased FACS CD44+ CD4 T cells - decreased FACS CD44+ CD4 T cells - increased FACS CD44+ CD8 MFI - decreased FACS CD44+ CD8 MFI - increased FACS CD44+ CD8 T cells - decreased FACS CD44+ CD8 T cells - increased FACS CD44+ T cells - decreased FACS CD44+ T cells - increased FACS CD44+ T MFI - decreased FACS CD44+ T MFI - increased FACS CD8+ T cells - decreased FACS CD8+ T cells - increased FACS CD8+ T cells in CD3+ T cells - decreased FACS CD8+ T cells in CD3+ T cells - increased FACS CD8a+ DCs (gated in CD11c+ cells) - decreased FACS CD8a+ DCs (gated in CD11c+ cells) - increased FACS central memory CD4 T cells in CD4 T cells - decreased FACS central memory CD4 T cells in CD4 T cells - increased FACS central memory CD8 T cells in CD8 T cells - decreased FACS central memory CD8 T cells in CD8 T cells - increased FACS effector memory CD4 T cells in CD4 T cells - decreased FACS effector memory CD4 T cells in CD4 T cells - increased FACS effector memory CD8 T cells in CD8 T cells - decreased FACS effector memory CD8 T cells in CD8 T cells - increased FACS effector T cells - decreased FACS effector T cells - increased FACS IgD MFI - decreased FACS IgD MFI - increased FACS IgD+ B cell percentage - decreased FACS IgD+ B cell percentage - increased FACS IgM MFI - decreased FACS IgM MFI - increased FACS IgM+ B cells - decreased FACS IgM+ B cells - increased FACS macrophages - decreased FACS macrophages - increased FACS memory T cells - decreased FACS memory T cells - increased FACS naive CD4 T cells in CD4 T cells - decreased FACS naive CD4 T cells in CD4 T cells - increased FACS naive CD8 T cells in CD8 T cells - decreased FACS naive CD8 T cells in CD8 T cells - increased FACS naive T cells - decreased FACS naive T cells - increased FACS neutrophils - decreased FACS neutrophils - increased FACS NK cells - decreased FACS NK cells - increased FACS NK1.1+ T cells - decreased FACS NK1.1+ T cells - increased FACS NKT cells (tet) - decreased FACS NKT cells (tet) - increased FACS pDCs - decreased FACS pDCs - increased FACS T cells - decreased FACS T cells - increased growth/size hearing/vestibular/ear hematopoietic competition - disadvantage hematopoietic system homeostasis/metabolism IgA response to 2nd OVA/Alum Challenge (day 7) - decreased IgA response to 2nd OVA/Alum Challenge (day 7) - increased IgE response to a Cysteine Protease (Papain) - decreased IgE response to a Cysteine Protease (Papain) - increased IgG1 response to a Cysteine Protease (Papain) - decreased IgG1 response to a Cysteine Protease (Papain) - increased immune system impaired response to dsDNA- type I IFN production by macrophages inflammatory bowel disease phenotype influenza proliferation in macrophages - decreased influenza proliferation in macrophages - increased influenza resistance iron deficiency iron excess LCMV clone 13 resistance lethality-embryonic/perinatal lethality-postnatal life span-post-weaning/aging limbs/digits/tail phenotype liver/biliary system LPS Cachexia: Body Weight (day 0) - decreased LPS Cachexia: Body Weight (day 0) - increased LPS Cachexia: Body Weight (day 0, z-score) - decreased LPS Cachexia: Body Weight (day 0, z-score) - increased LPS Cachexia: Body Weight (day 1) - decreased LPS Cachexia: Body Weight (day 1) - increased LPS Cachexia: Body Weight (day 14) - decreased LPS Cachexia: Body Weight (day 14) - increased LPS Cachexia: Body Weight (day 2) - decreased LPS Cachexia: Body Weight (day 2) - increased LPS Cachexia: Body Weight Change (day 1, g) - decreased LPS Cachexia: Body Weight Change (day 1, g) - increased LPS Cachexia: Body Weight Change (day 1, ratio) - decreased LPS Cachexia: Body Weight Change (day 1, ratio) - increased LPS Cachexia: Body Weight Change (day 14, g) - decreased LPS Cachexia: Body Weight Change (day 14, g) - increased LPS Cachexia: Body Weight Change (day 14, ratio) - decreased LPS Cachexia: Body Weight Change (day 14, ratio) - increased LPS Cachexia: Body Weight Change (day 2, g) - decreased LPS Cachexia: Body Weight Change (day 2, g) - increased LPS Cachexia: Body Weight Change (day 2, ratio) - decreased LPS Cachexia: Body Weight Change (day 2, ratio) - increased LPS Hypersensitivity - decreased LPS Hypersensitivity - increased LPS-induced Necroptosis - decreased LPS-induced Necroptosis - increased Macrophage necroptosis: high Macrophage necroptosis: low MC38 tumor body weight change (%) - decreased MC38 tumor body weight change (%) - increased MC38 tumor body weight change (%, female) - decreased MC38 tumor body weight change (%, female) - increased MC38 tumor body weight change (%, male) - decreased MC38 tumor body weight change (%, male) - increased MC38 tumor body weight change (g) - decreased MC38 tumor body weight change (g) - increased MC38 tumor body weight change (g, female) - decreased MC38 tumor body weight change (g, female) - increased MC38 tumor body weight change (g, male) - decreased MC38 tumor body weight change (g, male) - increased MC38 tumor volume (day 22) - decreased MC38 tumor volume (day 22) - increased MC38 tumor volume (day 22, early sac sick or found dead, IM injection, dermatitis, trimmed) - decreased MC38 tumor volume (day 22, early sac sick or found dead, IM injection, dermatitis, trimmed) - increased MCMV proliferation in macrophages - decreased MCMV proliferation in macrophages - increased MCMV resistance MCMV susceptibility MTT dsDNA PECs - decreased MTT dsDNA PECs - increased MTT Value of PECs - decreased MTT Value of PECs - increased muscle NALP3 inflammasome signaling defect nervous system NK cell response - decreased NK killing - decreased NK killing - increased Nlrc4 inflammasome: high response Nlrc4 inflammasome: low response NLRP3 inflammasome: high response NLRP3 inflammasome: low response no phenotypic analysis normal phenotype other phenotype OVA-specific IgE - decreased OVA-specific IgE - increased OVA-specific IgE after 2nd OVA/Alum - decreased OVA-specific IgE after 2nd OVA/Alum - increased Peritoneal exudates B1a cell % - decreased Peritoneal exudates B1a cell % - increased Peritoneal exudates B1a cell numbers - decreased Peritoneal exudates B1a cell numbers - increased Peritoneal exudates B1b cell % - decreased Peritoneal exudates B1b cell % - increased Peritoneal exudates B1b cell numbers - decreased Peritoneal exudates B1b cell numbers - increased Peritoneal exudates macrophage % - decreased Peritoneal exudates macrophage % - increased Peritoneal exudates macrophage numbers - decreased Peritoneal exudates macrophage numbers - increased Peritoneal exudates neutrophil % - decreased Peritoneal exudates neutrophil % - increased Peritoneal exudates neutrophil numbers - decreased Peritoneal exudates neutrophil numbers - increased phagocytosis in PECs - decreased phagocytosis in PECs - increased pigmentation polycythemia post-MCMV FACS B cells - decreased post-MCMV FACS B cells - increased post-MCMV FACS B:T cells - decreased post-MCMV FACS B:T cells - increased post-MCMV FACS B1 cells - decreased post-MCMV FACS B1 cells - increased post-MCMV FACS B1a cells - decreased post-MCMV FACS B1a cells - increased post-MCMV FACS B1a cells in B1 cells - decreased post-MCMV FACS B1a cells in B1 cells - increased post-MCMV FACS B1b cells - decreased post-MCMV FACS B1b cells - increased post-MCMV FACS B1b cells in B1 cells - decreased post-MCMV FACS B1b cells in B1 cells - increased post-MCMV FACS B2 cells - decreased post-MCMV FACS B2 cells - increased post-MCMV FACS B220 MFI - decreased post-MCMV FACS B220 MFI - increased post-MCMV FACS CD11b+ DCs (gated in CD11c+ cells) - decreased post-MCMV FACS CD11b+ DCs (gated in CD11c+ cells) - increased post-MCMV FACS CD11c+ DCs - decreased post-MCMV FACS CD11c+ DCs - increased post-MCMV FACS CD4:CD8 - decreased post-MCMV FACS CD4:CD8 - increased post-MCMV FACS CD4+ T cells - decreased post-MCMV FACS CD4+ T cells - increased post-MCMV FACS CD4+ T cells in CD3+ T cells - decreased post-MCMV FACS CD4+ T cells in CD3+ T cells - increased post-MCMV FACS CD44+ CD4 MFI - decreased post-MCMV FACS CD44+ CD4 MFI - increased post-MCMV FACS CD44+ CD4 T cells - decreased post-MCMV FACS CD44+ CD4 T cells - increased post-MCMV FACS CD44+ CD8 MFI - decreased post-MCMV FACS CD44+ CD8 MFI - increased post-MCMV FACS CD44+ CD8 T cells - decreased post-MCMV FACS CD44+ CD8 T cells - increased post-MCMV FACS CD44+ T cells - decreased post-MCMV FACS CD44+ T cells - increased post-MCMV FACS CD44+ T MFI - decreased post-MCMV FACS CD44+ T MFI - increased post-MCMV FACS CD8+ T cells - decreased post-MCMV FACS CD8+ T cells - increased post-MCMV FACS CD8+ T cells in CD3+ T cells - decreased post-MCMV FACS CD8+ T cells in CD3+ T cells - increased post-MCMV FACS CD8a+ DCs (gated in CD11c+ cells) - decreased post-MCMV FACS CD8a+ DCs (gated in CD11c+ cells) - increased post-MCMV FACS central memory CD4 T cells in CD4 T cells - decreased post-MCMV FACS central memory CD4 T cells in CD4 T cells - increased post-MCMV FACS central memory CD8 T cells in CD8 T cells - decreased post-MCMV FACS central memory CD8 T cells in CD8 T cells - increased post-MCMV FACS effector memory CD4 T cells in CD4 T cells - decreased post-MCMV FACS effector memory CD4 T cells in CD4 T cells - increased post-MCMV FACS effector memory CD8 T cells in CD8 T cells - decreased post-MCMV FACS effector memory CD8 T cells in CD8 T cells - increased post-MCMV FACS effector T cells - decreased post-MCMV FACS effector T cells - increased post-MCMV FACS IgD MFI - decreased post-MCMV FACS IgD MFI - increased post-MCMV FACS IgD+ B cell percentage - decreased post-MCMV FACS IgD+ B cell percentage - increased post-MCMV FACS IgM MFI - decreased post-MCMV FACS IgM MFI - increased post-MCMV FACS IgM+ B cells - decreased post-MCMV FACS IgM+ B cells - increased post-MCMV FACS macrophages - decreased post-MCMV FACS macrophages - increased post-MCMV FACS memory T cells - decreased post-MCMV FACS memory T cells - increased post-MCMV FACS naive CD4 T cells in CD4 T cells - decreased post-MCMV FACS naive CD4 T cells in CD4 T cells - increased post-MCMV FACS naive CD8 T cells in CD8 T cells - decreased post-MCMV FACS naive CD8 T cells in CD8 T cells - increased post-MCMV FACS naive T cells - decreased post-MCMV FACS naive T cells - increased post-MCMV FACS neutrophils - decreased post-MCMV FACS neutrophils - increased post-MCMV FACS NK cells - decreased post-MCMV FACS NK cells - increased post-MCMV FACS NK T cells - decreased post-MCMV FACS NK T cells - increased post-MCMV FACS NKT cells (tet) - decreased post-MCMV FACS NKT cells (tet) - increased post-MCMV FACS pDCs - decreased post-MCMV FACS pDCs - increased post-MCMV FACS T cells - decreased post-MCMV FACS T cells - increased ratio of OVA-specific IgE over the total IgE - decreased ratio of OVA-specific IgE over the total IgE - increased renal/urinary system reproductive system resistance to B10-F16 melanoma - decreased resistance to B10-F16 melanoma - increased respiratory system response to injected CpG DNA - decreased RVFV proliferation in macrophages - decreased RVFV proliferation in macrophages - increased RVFV susceptibility secretory SlgA after 2nd OVA/Alum Challenge (day 7) - decreased secretory SlgA after 2nd OVA/Alum Challenge (day 7) - increased skeleton phenotype skin/coat/nails taste/olfaction T-dependent humoral response defect- decreased antibody response to OVA+ alum immunization T-dependent humoral response defect- decreased antibody response to rSFV T-dependent humoral response defect- increased antibody response to OVA+ alum immunization T-dependent humoral response defect- increased antibody response to rSFV T-independent B cell response defect- decreased TNP-specific IgM to TNP-Ficoll immunization T-independent B cell response defect- increased TNP-specific IgM to TNP-Ficoll immunization TLR signaling defect: hypersensitivity to CpG + IFNg TLR signaling defect: hypersensitivity to LPS TLR signaling defect: hypersensitivity to MALP2 TLR signaling defect: hypersensitivity to PAM3CSK4 TLR signaling defect: hypersensitivity to poly I:C TLR signaling defect: hypersensitivity to poly I:C + IFNg TLR signaling defect: hypersensitivity to R848 TLR signaling defect: hyposensitivity to CpG + IFNg TLR signaling defect: hyposensitivity to LPS TLR signaling defect: hyposensitivity to MALP2 TLR signaling defect: hyposensitivity to PAM3CSK4 TLR signaling defect: hyposensitivity to poly I:C TLR signaling defect: hyposensitivity to poly I:C + IFNg TLR signaling defect: hyposensitivity to R848 TLR signaling defect: TNF production by macrophages total IgE after 2nd OVA/Alum - decreased total IgE after 2nd OVA/Alum - increased Total IgE After 2nd OVA/Alum Challenge (day 7) - decreased Total IgE After 2nd OVA/Alum Challenge (day 7) - increased total IgE level - decreased total IgE level - increased touch/vibrissae tumorigenesis vision/eye
and any of none of 125-03 Response - decreased 125-03 Response - increased 30 min GTT hyperglycemic 30 min GTT hyperglycemic (male) 30 min GTT hyperoglycemic (female) 30 min GTT hypoglycemic 30 min GTT hypoglycemic (female) 30 min GTT hypoglycemic (male) adenovirus infection of macrophages - decreased adenovirus infection of macrophages - increased adipose tissue anemia Anophthalmia Aut: Interaction - decreased Aut: Interaction - increased autoimmunity behavior/neurological Blood Analysis EO% - decreased Blood Analysis EO% - increased Blood Analysis Hb - decreased Blood Analysis Hb - increased Blood Analysis HCT - decreased Blood Analysis HCT - increased Blood Analysis LY# - decreased Blood Analysis LY# - increased Blood Analysis MCH - decreased Blood Analysis MCH - increased Blood Analysis MCHC - decreased Blood Analysis MCHC - increased Blood Analysis MCV - decreased Blood Analysis MCV - increased Blood Analysis MO# - decreased Blood Analysis MO# - increased Blood Analysis NE# - decreased Blood Analysis NE# - increased Blood Analysis Platelet Count - decreased Blood Analysis Platelet Count - increased Blood Analysis RBC - decreased Blood Analysis RBC - increased Blood Analysis RDW - decreased Blood Analysis RDW - increased Blood Analysis WBC - decreased Blood Analysis WBC - increased Blood Pressure: Pooled HR - decreased Blood Pressure: Pooled HR - increased Blood Pressure: Pooled SBP - decreased Blood Pressure: Pooled SBP - increased Body Weight - decreased Body Weight - increased Body Weight (BP, z-score, female) - decreased Body Weight (BP, z-score, female) - increased Body Weight (BP, z-score, male) - decreased Body Weight (BP, z-score, male) - increased Body Weight (DSS Female) - decreased Body Weight (DSS Female) - increased Body Weight (DSS Male) - decreased Body Weight (DSS Male) - increased Body Weight (DSS) - decreased Body Weight (DSS) - increased Body Weight (DSS, Day10) - decreased Body Weight (DSS, Day10) - increased Body Weight (DSS, Day7) - decreased Body Weight (DSS, Day7) - increased Body Weight (DSS, z-score) - decreased Body Weight (DSS, z-score) - increased Body Weight (DSS, z-score, female) - decreased Body Weight (DSS, z-score, female) - increased Body Weight (DSS, z-score, male) - decreased Body Weight (DSS, z-score, male) - increased Body Weight (Female) - decreased Body Weight (Female) - increased Body Weight (Male) - decreased Body Weight (Male) - increased Body Weight (Z-score) - decreased Body Weight (Z-score) - increased Body Weight (Z-score, female) - decreased Body Weight (Z-score, female) - increased Body Weight (Z-score, male) - decreased Body Weight (Z-score, male) - increased Bone: Femur Length (AI, residual) - decreased Bone: Femur Length (AI, residual) - increased Bone: Femur Length (AI, residual, female) - decreased Bone: Femur Length (AI, residual, female) - increased Bone: Femur Length (AI, residual, male) - decreased Bone: Femur Length (AI, residual, male) - increased Bone: Fore Hip Distance (AI) - decreased Bone: Fore Hip Distance (AI) - increased Bone: Fore Hip Distance (AI, female) - decreased Bone: Fore Hip Distance (AI, female) - increased Bone: Fore Hip Distance (AI, male) - decreased Bone: Fore Hip Distance (AI, male) - increased Bone: Hind Hip Distance (AI) - decreased Bone: Hind Hip Distance (AI) - increased Bone: Hind Hip Distance (AI, female) - decreased Bone: Hind Hip Distance (AI, female) - increased Bone: Hind Hip Distance (AI, male) - decreased Bone: Hind Hip Distance (AI, male) - increased Bone: Hip Ratio (AI) - decreased Bone: Hip Ratio (AI) - increased Bone: Pelvis Length (AI, residual) - decreased Bone: Pelvis Length (AI, residual) - increased Bone: Pelvis Length (AI, residual, female) - decreased Bone: Pelvis Length (AI, residual, female) - increased Bone: Pelvis Length (AI, residual, male) - decreased Bone: Pelvis Length (AI, residual, male) - increased Bone: Spine Deformity (female) Bone: Spine Deformity (male) Bone: Tibia Length (AI, residual) - decreased Bone: Tibia Length (AI, residual) - increased Bone: Tibia Length (AI, residual, female) - decreased Bone: Tibia Length (AI, residual, female) - increased Bone: Tibia Length (AI, residual, male) - decreased Bone: Tibia Length (AI, residual, male) - increased cardiovascular system CD8 response - decreased cellular phenotype craniofacial CTL killing - decreased CTL killing - increased CTL killing dominant epitope - decreased CTL killing dominant epitope - increased CTL killing subdominant epitope - decreased CTL killing subdominant epitope - increased digestive/alimentary dsDNA Antibody - decreased dsDNA Antibody - increased dsDNA induced type I IFN production - decreased dsDNA induced type I IFN production - increased DSS: resistant DSS: resistant day 10 DSS: resistant day 7 DSS: sensitive day 10 DSS: sensitive day 7 embryogenesis endocrine/exocrine gland extracellular cGAMP: high response extracellular cGAMP: low response eye: micro-ophthalmia Eye: SL-OCT BM to ILM thickness - decreased Eye: SL-OCT BM to ILM thickness - increased Eye: SL-OCT BM to ILM thickness (base) - decreased Eye: SL-OCT BM to ILM thickness (base) - increased Eye: SL-OCT BM to ILM thickness (delta) - decreased Eye: SL-OCT BM to ILM thickness (delta) - increased Eye: SL-OCT INL to ILM thickness - decreased Eye: SL-OCT INL to ILM thickness - increased Eye: SL-OCT INL to ILM thickness (base) - decreased Eye: SL-OCT INL to ILM thickness (base) - increased Eye: SL-OCT INL to ILM thickness (delta) - decreased Eye: SL-OCT INL to ILM thickness (delta) - increased Eye: SL-OCT IPL to ILM thickness - decreased Eye: SL-OCT IPL to ILM thickness - increased Eye: SL-OCT IPL to ILM thickness (base) - decreased Eye: SL-OCT IPL to ILM thickness (base) - increased Eye: SL-OCT IPL to ILM thickness (delta) - decreased Eye: SL-OCT IPL to ILM thickness (delta) - increased FACS B cells - decreased FACS B cells - increased FACS B:T cells - decreased FACS B:T cells - increased FACS B1 cells - decreased FACS B1 cells - increased FACS B1a cells - decreased FACS B1a cells - increased FACS B1a cells in B1 cells - decreased FACS B1a cells in B1 cells - increased FACS B1b cells - decreased FACS B1b cells - increased FACS B1b cells in B1 cells - decreased FACS B1b cells in B1 cells - increased FACS B2 cells - decreased FACS B2 cells - increased FACS B220 MFI - decreased FACS B220 MFI - increased FACS CD11b+ DCs (gated in CD11c+ cells) - decreased FACS CD11b+ DCs (gated in CD11c+ cells) - increased FACS CD11c+ DCs - decreased FACS CD11c+ DCs - increased FACS CD4:CD8 - decreased FACS CD4:CD8 - increased FACS CD4+ T cells - decreased FACS CD4+ T cells - increased FACS CD4+ T cells in CD3+ T cells - decreased FACS CD4+ T cells in CD3+ T cells - increased FACS CD44+ CD4 MFI - decreased FACS CD44+ CD4 MFI - increased FACS CD44+ CD4 T cells - decreased FACS CD44+ CD4 T cells - increased FACS CD44+ CD8 MFI - decreased FACS CD44+ CD8 MFI - increased FACS CD44+ CD8 T cells - decreased FACS CD44+ CD8 T cells - increased FACS CD44+ T cells - decreased FACS CD44+ T cells - increased FACS CD44+ T MFI - decreased FACS CD44+ T MFI - increased FACS CD8+ T cells - decreased FACS CD8+ T cells - increased FACS CD8+ T cells in CD3+ T cells - decreased FACS CD8+ T cells in CD3+ T cells - increased FACS CD8a+ DCs (gated in CD11c+ cells) - decreased FACS CD8a+ DCs (gated in CD11c+ cells) - increased FACS central memory CD4 T cells in CD4 T cells - decreased FACS central memory CD4 T cells in CD4 T cells - increased FACS central memory CD8 T cells in CD8 T cells - decreased FACS central memory CD8 T cells in CD8 T cells - increased FACS effector memory CD4 T cells in CD4 T cells - decreased FACS effector memory CD4 T cells in CD4 T cells - increased FACS effector memory CD8 T cells in CD8 T cells - decreased FACS effector memory CD8 T cells in CD8 T cells - increased FACS effector T cells - decreased FACS effector T cells - increased FACS IgD MFI - decreased FACS IgD MFI - increased FACS IgD+ B cell percentage - decreased FACS IgD+ B cell percentage - increased FACS IgM MFI - decreased FACS IgM MFI - increased FACS IgM+ B cells - decreased FACS IgM+ B cells - increased FACS macrophages - decreased FACS macrophages - increased FACS memory T cells - decreased FACS memory T cells - increased FACS naive CD4 T cells in CD4 T cells - decreased FACS naive CD4 T cells in CD4 T cells - increased FACS naive CD8 T cells in CD8 T cells - decreased FACS naive CD8 T cells in CD8 T cells - increased FACS naive T cells - decreased FACS naive T cells - increased FACS neutrophils - decreased FACS neutrophils - increased FACS NK cells - decreased FACS NK cells - increased FACS NK1.1+ T cells - decreased FACS NK1.1+ T cells - increased FACS NKT cells (tet) - decreased FACS NKT cells (tet) - increased FACS pDCs - decreased FACS pDCs - increased FACS T cells - decreased FACS T cells - increased growth/size hearing/vestibular/ear hematopoietic competition - disadvantage hematopoietic system homeostasis/metabolism IgA response to 2nd OVA/Alum Challenge (day 7) - decreased IgA response to 2nd OVA/Alum Challenge (day 7) - increased IgE response to a Cysteine Protease (Papain) - decreased IgE response to a Cysteine Protease (Papain) - increased IgG1 response to a Cysteine Protease (Papain) - decreased IgG1 response to a Cysteine Protease (Papain) - increased immune system impaired response to dsDNA- type I IFN production by macrophages inflammatory bowel disease phenotype influenza proliferation in macrophages - decreased influenza proliferation in macrophages - increased influenza resistance iron deficiency iron excess LCMV clone 13 resistance lethality-embryonic/perinatal lethality-postnatal life span-post-weaning/aging limbs/digits/tail phenotype liver/biliary system LPS Cachexia: Body Weight (day 0) - decreased LPS Cachexia: Body Weight (day 0) - increased LPS Cachexia: Body Weight (day 0, z-score) - decreased LPS Cachexia: Body Weight (day 0, z-score) - increased LPS Cachexia: Body Weight (day 1) - decreased LPS Cachexia: Body Weight (day 1) - increased LPS Cachexia: Body Weight (day 14) - decreased LPS Cachexia: Body Weight (day 14) - increased LPS Cachexia: Body Weight (day 2) - decreased LPS Cachexia: Body Weight (day 2) - increased LPS Cachexia: Body Weight Change (day 1, g) - decreased LPS Cachexia: Body Weight Change (day 1, g) - increased LPS Cachexia: Body Weight Change (day 1, ratio) - decreased LPS Cachexia: Body Weight Change (day 1, ratio) - increased LPS Cachexia: Body Weight Change (day 14, g) - decreased LPS Cachexia: Body Weight Change (day 14, g) - increased LPS Cachexia: Body Weight Change (day 14, ratio) - decreased LPS Cachexia: Body Weight Change (day 14, ratio) - increased LPS Cachexia: Body Weight Change (day 2, g) - decreased LPS Cachexia: Body Weight Change (day 2, g) - increased LPS Cachexia: Body Weight Change (day 2, ratio) - decreased LPS Cachexia: Body Weight Change (day 2, ratio) - increased LPS Hypersensitivity - decreased LPS Hypersensitivity - increased LPS-induced Necroptosis - decreased LPS-induced Necroptosis - increased Macrophage necroptosis: high Macrophage necroptosis: low MC38 tumor body weight change (%) - decreased MC38 tumor body weight change (%) - increased MC38 tumor body weight change (%, female) - decreased MC38 tumor body weight change (%, female) - increased MC38 tumor body weight change (%, male) - decreased MC38 tumor body weight change (%, male) - increased MC38 tumor body weight change (g) - decreased MC38 tumor body weight change (g) - increased MC38 tumor body weight change (g, female) - decreased MC38 tumor body weight change (g, female) - increased MC38 tumor body weight change (g, male) - decreased MC38 tumor body weight change (g, male) - increased MC38 tumor volume (day 22) - decreased MC38 tumor volume (day 22) - increased MC38 tumor volume (day 22, early sac sick or found dead, IM injection, dermatitis, trimmed) - decreased MC38 tumor volume (day 22, early sac sick or found dead, IM injection, dermatitis, trimmed) - increased MCMV proliferation in macrophages - decreased MCMV proliferation in macrophages - increased MCMV resistance MCMV susceptibility MTT dsDNA PECs - decreased MTT dsDNA PECs - increased MTT Value of PECs - decreased MTT Value of PECs - increased muscle NALP3 inflammasome signaling defect nervous system NK cell response - decreased NK killing - decreased NK killing - increased Nlrc4 inflammasome: high response Nlrc4 inflammasome: low response NLRP3 inflammasome: high response NLRP3 inflammasome: low response no phenotypic analysis normal phenotype other phenotype OVA-specific IgE - decreased OVA-specific IgE - increased OVA-specific IgE after 2nd OVA/Alum - decreased OVA-specific IgE after 2nd OVA/Alum - increased Peritoneal exudates B1a cell % - decreased Peritoneal exudates B1a cell % - increased Peritoneal exudates B1a cell numbers - decreased Peritoneal exudates B1a cell numbers - increased Peritoneal exudates B1b cell % - decreased Peritoneal exudates B1b cell % - increased Peritoneal exudates B1b cell numbers - decreased Peritoneal exudates B1b cell numbers - increased Peritoneal exudates macrophage % - decreased Peritoneal exudates macrophage % - increased Peritoneal exudates macrophage numbers - decreased Peritoneal exudates macrophage numbers - increased Peritoneal exudates neutrophil % - decreased Peritoneal exudates neutrophil % - increased Peritoneal exudates neutrophil numbers - decreased Peritoneal exudates neutrophil numbers - increased phagocytosis in PECs - decreased phagocytosis in PECs - increased pigmentation polycythemia post-MCMV FACS B cells - decreased post-MCMV FACS B cells - increased post-MCMV FACS B:T cells - decreased post-MCMV FACS B:T cells - increased post-MCMV FACS B1 cells - decreased post-MCMV FACS B1 cells - increased post-MCMV FACS B1a cells - decreased post-MCMV FACS B1a cells - increased post-MCMV FACS B1a cells in B1 cells - decreased post-MCMV FACS B1a cells in B1 cells - increased post-MCMV FACS B1b cells - decreased post-MCMV FACS B1b cells - increased post-MCMV FACS B1b cells in B1 cells - decreased post-MCMV FACS B1b cells in B1 cells - increased post-MCMV FACS B2 cells - decreased post-MCMV FACS B2 cells - increased post-MCMV FACS B220 MFI - decreased post-MCMV FACS B220 MFI - increased post-MCMV FACS CD11b+ DCs (gated in CD11c+ cells) - decreased post-MCMV FACS CD11b+ DCs (gated in CD11c+ cells) - increased post-MCMV FACS CD11c+ DCs - decreased post-MCMV FACS CD11c+ DCs - increased post-MCMV FACS CD4:CD8 - decreased post-MCMV FACS CD4:CD8 - increased post-MCMV FACS CD4+ T cells - decreased post-MCMV FACS CD4+ T cells - increased post-MCMV FACS CD4+ T cells in CD3+ T cells - decreased post-MCMV FACS CD4+ T cells in CD3+ T cells - increased post-MCMV FACS CD44+ CD4 MFI - decreased post-MCMV FACS CD44+ CD4 MFI - increased post-MCMV FACS CD44+ CD4 T cells - decreased post-MCMV FACS CD44+ CD4 T cells - increased post-MCMV FACS CD44+ CD8 MFI - decreased post-MCMV FACS CD44+ CD8 MFI - increased post-MCMV FACS CD44+ CD8 T cells - decreased post-MCMV FACS CD44+ CD8 T cells - increased post-MCMV FACS CD44+ T cells - decreased post-MCMV FACS CD44+ T cells - increased post-MCMV FACS CD44+ T MFI - decreased post-MCMV FACS CD44+ T MFI - increased post-MCMV FACS CD8+ T cells - decreased post-MCMV FACS CD8+ T cells - increased post-MCMV FACS CD8+ T cells in CD3+ T cells - decreased post-MCMV FACS CD8+ T cells in CD3+ T cells - increased post-MCMV FACS CD8a+ DCs (gated in CD11c+ cells) - decreased post-MCMV FACS CD8a+ DCs (gated in CD11c+ cells) - increased post-MCMV FACS central memory CD4 T cells in CD4 T cells - decreased post-MCMV FACS central memory CD4 T cells in CD4 T cells - increased post-MCMV FACS central memory CD8 T cells in CD8 T cells - decreased post-MCMV FACS central memory CD8 T cells in CD8 T cells - increased post-MCMV FACS effector memory CD4 T cells in CD4 T cells - decreased post-MCMV FACS effector memory CD4 T cells in CD4 T cells - increased post-MCMV FACS effector memory CD8 T cells in CD8 T cells - decreased post-MCMV FACS effector memory CD8 T cells in CD8 T cells - increased post-MCMV FACS effector T cells - decreased post-MCMV FACS effector T cells - increased post-MCMV FACS IgD MFI - decreased post-MCMV FACS IgD MFI - increased post-MCMV FACS IgD+ B cell percentage - decreased post-MCMV FACS IgD+ B cell percentage - increased post-MCMV FACS IgM MFI - decreased post-MCMV FACS IgM MFI - increased post-MCMV FACS IgM+ B cells - decreased post-MCMV FACS IgM+ B cells - increased post-MCMV FACS macrophages - decreased post-MCMV FACS macrophages - increased post-MCMV FACS memory T cells - decreased post-MCMV FACS memory T cells - increased post-MCMV FACS naive CD4 T cells in CD4 T cells - decreased post-MCMV FACS naive CD4 T cells in CD4 T cells - increased post-MCMV FACS naive CD8 T cells in CD8 T cells - decreased post-MCMV FACS naive CD8 T cells in CD8 T cells - increased post-MCMV FACS naive T cells - decreased post-MCMV FACS naive T cells - increased post-MCMV FACS neutrophils - decreased post-MCMV FACS neutrophils - increased post-MCMV FACS NK cells - decreased post-MCMV FACS NK cells - increased post-MCMV FACS NK T cells - decreased post-MCMV FACS NK T cells - increased post-MCMV FACS NKT cells (tet) - decreased post-MCMV FACS NKT cells (tet) - increased post-MCMV FACS pDCs - decreased post-MCMV FACS pDCs - increased post-MCMV FACS T cells - decreased post-MCMV FACS T cells - increased ratio of OVA-specific IgE over the total IgE - decreased ratio of OVA-specific IgE over the total IgE - increased renal/urinary system reproductive system resistance to B10-F16 melanoma - decreased resistance to B10-F16 melanoma - increased respiratory system response to injected CpG DNA - decreased RVFV proliferation in macrophages - decreased RVFV proliferation in macrophages - increased RVFV susceptibility secretory SlgA after 2nd OVA/Alum Challenge (day 7) - decreased secretory SlgA after 2nd OVA/Alum Challenge (day 7) - increased skeleton phenotype skin/coat/nails taste/olfaction T-dependent humoral response defect- decreased antibody response to OVA+ alum immunization T-dependent humoral response defect- decreased antibody response to rSFV T-dependent humoral response defect- increased antibody response to OVA+ alum immunization T-dependent humoral response defect- increased antibody response to rSFV T-independent B cell response defect- decreased TNP-specific IgM to TNP-Ficoll immunization T-independent B cell response defect- increased TNP-specific IgM to TNP-Ficoll immunization TLR signaling defect: hypersensitivity to CpG + IFNg TLR signaling defect: hypersensitivity to LPS TLR signaling defect: hypersensitivity to MALP2 TLR signaling defect: hypersensitivity to PAM3CSK4 TLR signaling defect: hypersensitivity to poly I:C TLR signaling defect: hypersensitivity to poly I:C + IFNg TLR signaling defect: hypersensitivity to R848 TLR signaling defect: hyposensitivity to CpG + IFNg TLR signaling defect: hyposensitivity to LPS TLR signaling defect: hyposensitivity to MALP2 TLR signaling defect: hyposensitivity to PAM3CSK4 TLR signaling defect: hyposensitivity to poly I:C TLR signaling defect: hyposensitivity to poly I:C + IFNg TLR signaling defect: hyposensitivity to R848 TLR signaling defect: TNF production by macrophages total IgE after 2nd OVA/Alum - decreased total IgE after 2nd OVA/Alum - increased Total IgE After 2nd OVA/Alum Challenge (day 7) - decreased Total IgE After 2nd OVA/Alum Challenge (day 7) - increased total IgE level - decreased total IgE level - increased touch/vibrissae tumorigenesis vision/eye
and none of any of 125-03 Response - decreased 125-03 Response - increased 30 min GTT hyperglycemic 30 min GTT hyperglycemic (male) 30 min GTT hyperoglycemic (female) 30 min GTT hypoglycemic 30 min GTT hypoglycemic (female) 30 min GTT hypoglycemic (male) adenovirus infection of macrophages - decreased adenovirus infection of macrophages - increased adipose tissue anemia Anophthalmia Aut: Interaction - decreased Aut: Interaction - increased autoimmunity behavior/neurological Blood Analysis EO% - decreased Blood Analysis EO% - increased Blood Analysis Hb - decreased Blood Analysis Hb - increased Blood Analysis HCT - decreased Blood Analysis HCT - increased Blood Analysis LY# - decreased Blood Analysis LY# - increased Blood Analysis MCH - decreased Blood Analysis MCH - increased Blood Analysis MCHC - decreased Blood Analysis MCHC - increased Blood Analysis MCV - decreased Blood Analysis MCV - increased Blood Analysis MO# - decreased Blood Analysis MO# - increased Blood Analysis NE# - decreased Blood Analysis NE# - increased Blood Analysis Platelet Count - decreased Blood Analysis Platelet Count - increased Blood Analysis RBC - decreased Blood Analysis RBC - increased Blood Analysis RDW - decreased Blood Analysis RDW - increased Blood Analysis WBC - decreased Blood Analysis WBC - increased Blood Pressure: Pooled HR - decreased Blood Pressure: Pooled HR - increased Blood Pressure: Pooled SBP - decreased Blood Pressure: Pooled SBP - increased Body Weight - decreased Body Weight - increased Body Weight (BP, z-score, female) - decreased Body Weight (BP, z-score, female) - increased Body Weight (BP, z-score, male) - decreased Body Weight (BP, z-score, male) - increased Body Weight (DSS Female) - decreased Body Weight (DSS Female) - increased Body Weight (DSS Male) - decreased Body Weight (DSS Male) - increased Body Weight (DSS) - decreased Body Weight (DSS) - increased Body Weight (DSS, Day10) - decreased Body Weight (DSS, Day10) - increased Body Weight (DSS, Day7) - decreased Body Weight (DSS, Day7) - increased Body Weight (DSS, z-score) - decreased Body Weight (DSS, z-score) - increased Body Weight (DSS, z-score, female) - decreased Body Weight (DSS, z-score, female) - increased Body Weight (DSS, z-score, male) - decreased Body Weight (DSS, z-score, male) - increased Body Weight (Female) - decreased Body Weight (Female) - increased Body Weight (Male) - decreased Body Weight (Male) - increased Body Weight (Z-score) - decreased Body Weight (Z-score) - increased Body Weight (Z-score, female) - decreased Body Weight (Z-score, female) - increased Body Weight (Z-score, male) - decreased Body Weight (Z-score, male) - increased Bone: Femur Length (AI, residual) - decreased Bone: Femur Length (AI, residual) - increased Bone: Femur Length (AI, residual, female) - decreased Bone: Femur Length (AI, residual, female) - increased Bone: Femur Length (AI, residual, male) - decreased Bone: Femur Length (AI, residual, male) - increased Bone: Fore Hip Distance (AI) - decreased Bone: Fore Hip Distance (AI) - increased Bone: Fore Hip Distance (AI, female) - decreased Bone: Fore Hip Distance (AI, female) - increased Bone: Fore Hip Distance (AI, male) - decreased Bone: Fore Hip Distance (AI, male) - increased Bone: Hind Hip Distance (AI) - decreased Bone: Hind Hip Distance (AI) - increased Bone: Hind Hip Distance (AI, female) - decreased Bone: Hind Hip Distance (AI, female) - increased Bone: Hind Hip Distance (AI, male) - decreased Bone: Hind Hip Distance (AI, male) - increased Bone: Hip Ratio (AI) - decreased Bone: Hip Ratio (AI) - increased Bone: Pelvis Length (AI, residual) - decreased Bone: Pelvis Length (AI, residual) - increased Bone: Pelvis Length (AI, residual, female) - decreased Bone: Pelvis Length (AI, residual, female) - increased Bone: Pelvis Length (AI, residual, male) - decreased Bone: Pelvis Length (AI, residual, male) - increased Bone: Spine Deformity (female) Bone: Spine Deformity (male) Bone: Tibia Length (AI, residual) - decreased Bone: Tibia Length (AI, residual) - increased Bone: Tibia Length (AI, residual, female) - decreased Bone: Tibia Length (AI, residual, female) - increased Bone: Tibia Length (AI, residual, male) - decreased Bone: Tibia Length (AI, residual, male) - increased cardiovascular system CD8 response - decreased cellular phenotype craniofacial CTL killing - decreased CTL killing - increased CTL killing dominant epitope - decreased CTL killing dominant epitope - increased CTL killing subdominant epitope - decreased CTL killing subdominant epitope - increased digestive/alimentary dsDNA Antibody - decreased dsDNA Antibody - increased dsDNA induced type I IFN production - decreased dsDNA induced type I IFN production - increased DSS: resistant DSS: resistant day 10 DSS: resistant day 7 DSS: sensitive day 10 DSS: sensitive day 7 embryogenesis endocrine/exocrine gland extracellular cGAMP: high response extracellular cGAMP: low response eye: micro-ophthalmia Eye: SL-OCT BM to ILM thickness - decreased Eye: SL-OCT BM to ILM thickness - increased Eye: SL-OCT BM to ILM thickness (base) - decreased Eye: SL-OCT BM to ILM thickness (base) - increased Eye: SL-OCT BM to ILM thickness (delta) - decreased Eye: SL-OCT BM to ILM thickness (delta) - increased Eye: SL-OCT INL to ILM thickness - decreased Eye: SL-OCT INL to ILM thickness - increased Eye: SL-OCT INL to ILM thickness (base) - decreased Eye: SL-OCT INL to ILM thickness (base) - increased Eye: SL-OCT INL to ILM thickness (delta) - decreased Eye: SL-OCT INL to ILM thickness (delta) - increased Eye: SL-OCT IPL to ILM thickness - decreased Eye: SL-OCT IPL to ILM thickness - increased Eye: SL-OCT IPL to ILM thickness (base) - decreased Eye: SL-OCT IPL to ILM thickness (base) - increased Eye: SL-OCT IPL to ILM thickness (delta) - decreased Eye: SL-OCT IPL to ILM thickness (delta) - increased FACS B cells - decreased FACS B cells - increased FACS B:T cells - decreased FACS B:T cells - increased FACS B1 cells - decreased FACS B1 cells - increased FACS B1a cells - decreased FACS B1a cells - increased FACS B1a cells in B1 cells - decreased FACS B1a cells in B1 cells - increased FACS B1b cells - decreased FACS B1b cells - increased FACS B1b cells in B1 cells - decreased FACS B1b cells in B1 cells - increased FACS B2 cells - decreased FACS B2 cells - increased FACS B220 MFI - decreased FACS B220 MFI - increased FACS CD11b+ DCs (gated in CD11c+ cells) - decreased FACS CD11b+ DCs (gated in CD11c+ cells) - increased FACS CD11c+ DCs - decreased FACS CD11c+ DCs - increased FACS CD4:CD8 - decreased FACS CD4:CD8 - increased FACS CD4+ T cells - decreased FACS CD4+ T cells - increased FACS CD4+ T cells in CD3+ T cells - decreased FACS CD4+ T cells in CD3+ T cells - increased FACS CD44+ CD4 MFI - decreased FACS CD44+ CD4 MFI - increased FACS CD44+ CD4 T cells - decreased FACS CD44+ CD4 T cells - increased FACS CD44+ CD8 MFI - decreased FACS CD44+ CD8 MFI - increased FACS CD44+ CD8 T cells - decreased FACS CD44+ CD8 T cells - increased FACS CD44+ T cells - decreased FACS CD44+ T cells - increased FACS CD44+ T MFI - decreased FACS CD44+ T MFI - increased FACS CD8+ T cells - decreased FACS CD8+ T cells - increased FACS CD8+ T cells in CD3+ T cells - decreased FACS CD8+ T cells in CD3+ T cells - increased FACS CD8a+ DCs (gated in CD11c+ cells) - decreased FACS CD8a+ DCs (gated in CD11c+ cells) - increased FACS central memory CD4 T cells in CD4 T cells - decreased FACS central memory CD4 T cells in CD4 T cells - increased FACS central memory CD8 T cells in CD8 T cells - decreased FACS central memory CD8 T cells in CD8 T cells - increased FACS effector memory CD4 T cells in CD4 T cells - decreased FACS effector memory CD4 T cells in CD4 T cells - increased FACS effector memory CD8 T cells in CD8 T cells - decreased FACS effector memory CD8 T cells in CD8 T cells - increased FACS effector T cells - decreased FACS effector T cells - increased FACS IgD MFI - decreased FACS IgD MFI - increased FACS IgD+ B cell percentage - decreased FACS IgD+ B cell percentage - increased FACS IgM MFI - decreased FACS IgM MFI - increased FACS IgM+ B cells - decreased FACS IgM+ B cells - increased FACS macrophages - decreased FACS macrophages - increased FACS memory T cells - decreased FACS memory T cells - increased FACS naive CD4 T cells in CD4 T cells - decreased FACS naive CD4 T cells in CD4 T cells - increased FACS naive CD8 T cells in CD8 T cells - decreased FACS naive CD8 T cells in CD8 T cells - increased FACS naive T cells - decreased FACS naive T cells - increased FACS neutrophils - decreased FACS neutrophils - increased FACS NK cells - decreased FACS NK cells - increased FACS NK1.1+ T cells - decreased FACS NK1.1+ T cells - increased FACS NKT cells (tet) - decreased FACS NKT cells (tet) - increased FACS pDCs - decreased FACS pDCs - increased FACS T cells - decreased FACS T cells - increased growth/size hearing/vestibular/ear hematopoietic competition - disadvantage hematopoietic system homeostasis/metabolism IgA response to 2nd OVA/Alum Challenge (day 7) - decreased IgA response to 2nd OVA/Alum Challenge (day 7) - increased IgE response to a Cysteine Protease (Papain) - decreased IgE response to a Cysteine Protease (Papain) - increased IgG1 response to a Cysteine Protease (Papain) - decreased IgG1 response to a Cysteine Protease (Papain) - increased immune system impaired response to dsDNA- type I IFN production by macrophages inflammatory bowel disease phenotype influenza proliferation in macrophages - decreased influenza proliferation in macrophages - increased influenza resistance iron deficiency iron excess LCMV clone 13 resistance lethality-embryonic/perinatal lethality-postnatal life span-post-weaning/aging limbs/digits/tail phenotype liver/biliary system LPS Cachexia: Body Weight (day 0) - decreased LPS Cachexia: Body Weight (day 0) - increased LPS Cachexia: Body Weight (day 0, z-score) - decreased LPS Cachexia: Body Weight (day 0, z-score) - increased LPS Cachexia: Body Weight (day 1) - decreased LPS Cachexia: Body Weight (day 1) - increased LPS Cachexia: Body Weight (day 14) - decreased LPS Cachexia: Body Weight (day 14) - increased LPS Cachexia: Body Weight (day 2) - decreased LPS Cachexia: Body Weight (day 2) - increased LPS Cachexia: Body Weight Change (day 1, g) - decreased LPS Cachexia: Body Weight Change (day 1, g) - increased LPS Cachexia: Body Weight Change (day 1, ratio) - decreased LPS Cachexia: Body Weight Change (day 1, ratio) - increased LPS Cachexia: Body Weight Change (day 14, g) - decreased LPS Cachexia: Body Weight Change (day 14, g) - increased LPS Cachexia: Body Weight Change (day 14, ratio) - decreased LPS Cachexia: Body Weight Change (day 14, ratio) - increased LPS Cachexia: Body Weight Change (day 2, g) - decreased LPS Cachexia: Body Weight Change (day 2, g) - increased LPS Cachexia: Body Weight Change (day 2, ratio) - decreased LPS Cachexia: Body Weight Change (day 2, ratio) - increased LPS Hypersensitivity - decreased LPS Hypersensitivity - increased LPS-induced Necroptosis - decreased LPS-induced Necroptosis - increased Macrophage necroptosis: high Macrophage necroptosis: low MC38 tumor body weight change (%) - decreased MC38 tumor body weight change (%) - increased MC38 tumor body weight change (%, female) - decreased MC38 tumor body weight change (%, female) - increased MC38 tumor body weight change (%, male) - decreased MC38 tumor body weight change (%, male) - increased MC38 tumor body weight change (g) - decreased MC38 tumor body weight change (g) - increased MC38 tumor body weight change (g, female) - decreased MC38 tumor body weight change (g, female) - increased MC38 tumor body weight change (g, male) - decreased MC38 tumor body weight change (g, male) - increased MC38 tumor volume (day 22) - decreased MC38 tumor volume (day 22) - increased MC38 tumor volume (day 22, early sac sick or found dead, IM injection, dermatitis, trimmed) - decreased MC38 tumor volume (day 22, early sac sick or found dead, IM injection, dermatitis, trimmed) - increased MCMV proliferation in macrophages - decreased MCMV proliferation in macrophages - increased MCMV resistance MCMV susceptibility MTT dsDNA PECs - decreased MTT dsDNA PECs - increased MTT Value of PECs - decreased MTT Value of PECs - increased muscle NALP3 inflammasome signaling defect nervous system NK cell response - decreased NK killing - decreased NK killing - increased Nlrc4 inflammasome: high response Nlrc4 inflammasome: low response NLRP3 inflammasome: high response NLRP3 inflammasome: low response no phenotypic analysis normal phenotype other phenotype OVA-specific IgE - decreased OVA-specific IgE - increased OVA-specific IgE after 2nd OVA/Alum - decreased OVA-specific IgE after 2nd OVA/Alum - increased Peritoneal exudates B1a cell % - decreased Peritoneal exudates B1a cell % - increased Peritoneal exudates B1a cell numbers - decreased Peritoneal exudates B1a cell numbers - increased Peritoneal exudates B1b cell % - decreased Peritoneal exudates B1b cell % - increased Peritoneal exudates B1b cell numbers - decreased Peritoneal exudates B1b cell numbers - increased Peritoneal exudates macrophage % - decreased Peritoneal exudates macrophage % - increased Peritoneal exudates macrophage numbers - decreased Peritoneal exudates macrophage numbers - increased Peritoneal exudates neutrophil % - decreased Peritoneal exudates neutrophil % - increased Peritoneal exudates neutrophil numbers - decreased Peritoneal exudates neutrophil numbers - increased phagocytosis in PECs - decreased phagocytosis in PECs - increased pigmentation polycythemia post-MCMV FACS B cells - decreased post-MCMV FACS B cells - increased post-MCMV FACS B:T cells - decreased post-MCMV FACS B:T cells - increased post-MCMV FACS B1 cells - decreased post-MCMV FACS B1 cells - increased post-MCMV FACS B1a cells - decreased post-MCMV FACS B1a cells - increased post-MCMV FACS B1a cells in B1 cells - decreased post-MCMV FACS B1a cells in B1 cells - increased post-MCMV FACS B1b cells - decreased post-MCMV FACS B1b cells - increased post-MCMV FACS B1b cells in B1 cells - decreased post-MCMV FACS B1b cells in B1 cells - increased post-MCMV FACS B2 cells - decreased post-MCMV FACS B2 cells - increased post-MCMV FACS B220 MFI - decreased post-MCMV FACS B220 MFI - increased post-MCMV FACS CD11b+ DCs (gated in CD11c+ cells) - decreased post-MCMV FACS CD11b+ DCs (gated in CD11c+ cells) - increased post-MCMV FACS CD11c+ DCs - decreased post-MCMV FACS CD11c+ DCs - increased post-MCMV FACS CD4:CD8 - decreased post-MCMV FACS CD4:CD8 - increased post-MCMV FACS CD4+ T cells - decreased post-MCMV FACS CD4+ T cells - increased post-MCMV FACS CD4+ T cells in CD3+ T cells - decreased post-MCMV FACS CD4+ T cells in CD3+ T cells - increased post-MCMV FACS CD44+ CD4 MFI - decreased post-MCMV FACS CD44+ CD4 MFI - increased post-MCMV FACS CD44+ CD4 T cells - decreased post-MCMV FACS CD44+ CD4 T cells - increased post-MCMV FACS CD44+ CD8 MFI - decreased post-MCMV FACS CD44+ CD8 MFI - increased post-MCMV FACS CD44+ CD8 T cells - decreased post-MCMV FACS CD44+ CD8 T cells - increased post-MCMV FACS CD44+ T cells - decreased post-MCMV FACS CD44+ T cells - increased post-MCMV FACS CD44+ T MFI - decreased post-MCMV FACS CD44+ T MFI - increased post-MCMV FACS CD8+ T cells - decreased post-MCMV FACS CD8+ T cells - increased post-MCMV FACS CD8+ T cells in CD3+ T cells - decreased post-MCMV FACS CD8+ T cells in CD3+ T cells - increased post-MCMV FACS CD8a+ DCs (gated in CD11c+ cells) - decreased post-MCMV FACS CD8a+ DCs (gated in CD11c+ cells) - increased post-MCMV FACS central memory CD4 T cells in CD4 T cells - decreased post-MCMV FACS central memory CD4 T cells in CD4 T cells - increased post-MCMV FACS central memory CD8 T cells in CD8 T cells - decreased post-MCMV FACS central memory CD8 T cells in CD8 T cells - increased post-MCMV FACS effector memory CD4 T cells in CD4 T cells - decreased post-MCMV FACS effector memory CD4 T cells in CD4 T cells - increased post-MCMV FACS effector memory CD8 T cells in CD8 T cells - decreased post-MCMV FACS effector memory CD8 T cells in CD8 T cells - increased post-MCMV FACS effector T cells - decreased post-MCMV FACS effector T cells - increased post-MCMV FACS IgD MFI - decreased post-MCMV FACS IgD MFI - increased post-MCMV FACS IgD+ B cell percentage - decreased post-MCMV FACS IgD+ B cell percentage - increased post-MCMV FACS IgM MFI - decreased post-MCMV FACS IgM MFI - increased post-MCMV FACS IgM+ B cells - decreased post-MCMV FACS IgM+ B cells - increased post-MCMV FACS macrophages - decreased post-MCMV FACS macrophages - increased post-MCMV FACS memory T cells - decreased post-MCMV FACS memory T cells - increased post-MCMV FACS naive CD4 T cells in CD4 T cells - decreased post-MCMV FACS naive CD4 T cells in CD4 T cells - increased post-MCMV FACS naive CD8 T cells in CD8 T cells - decreased post-MCMV FACS naive CD8 T cells in CD8 T cells - increased post-MCMV FACS naive T cells - decreased post-MCMV FACS naive T cells - increased post-MCMV FACS neutrophils - decreased post-MCMV FACS neutrophils - increased post-MCMV FACS NK cells - decreased post-MCMV FACS NK cells - increased post-MCMV FACS NK T cells - decreased post-MCMV FACS NK T cells - increased post-MCMV FACS NKT cells (tet) - decreased post-MCMV FACS NKT cells (tet) - increased post-MCMV FACS pDCs - decreased post-MCMV FACS pDCs - increased post-MCMV FACS T cells - decreased post-MCMV FACS T cells - increased ratio of OVA-specific IgE over the total IgE - decreased ratio of OVA-specific IgE over the total IgE - increased renal/urinary system reproductive system resistance to B10-F16 melanoma - decreased resistance to B10-F16 melanoma - increased respiratory system response to injected CpG DNA - decreased RVFV proliferation in macrophages - decreased RVFV proliferation in macrophages - increased RVFV susceptibility secretory SlgA after 2nd OVA/Alum Challenge (day 7) - decreased secretory SlgA after 2nd OVA/Alum Challenge (day 7) - increased skeleton phenotype skin/coat/nails taste/olfaction T-dependent humoral response defect- decreased antibody response to OVA+ alum immunization T-dependent humoral response defect- decreased antibody response to rSFV T-dependent humoral response defect- increased antibody response to OVA+ alum immunization T-dependent humoral response defect- increased antibody response to rSFV T-independent B cell response defect- decreased TNP-specific IgM to TNP-Ficoll immunization T-independent B cell response defect- increased TNP-specific IgM to TNP-Ficoll immunization TLR signaling defect: hypersensitivity to CpG + IFNg TLR signaling defect: hypersensitivity to LPS TLR signaling defect: hypersensitivity to MALP2 TLR signaling defect: hypersensitivity to PAM3CSK4 TLR signaling defect: hypersensitivity to poly I:C TLR signaling defect: hypersensitivity to poly I:C + IFNg TLR signaling defect: hypersensitivity to R848 TLR signaling defect: hyposensitivity to CpG + IFNg TLR signaling defect: hyposensitivity to LPS TLR signaling defect: hyposensitivity to MALP2 TLR signaling defect: hyposensitivity to PAM3CSK4 TLR signaling defect: hyposensitivity to poly I:C TLR signaling defect: hyposensitivity to poly I:C + IFNg TLR signaling defect: hyposensitivity to R848 TLR signaling defect: TNF production by macrophages total IgE after 2nd OVA/Alum - decreased total IgE after 2nd OVA/Alum - increased Total IgE After 2nd OVA/Alum Challenge (day 7) - decreased Total IgE After 2nd OVA/Alum Challenge (day 7) - increased total IgE level - decreased total IgE level - increased touch/vibrissae tumorigenesis vision/eye
and validated validated (with ENU) validated (without ENU) excluded untested (pending) untested (not pending) validated validated (with ENU) validated (without ENU) excluded untested